lansoprazole has been researched along with Esophageal Dysmotility in 4 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the relationship between the severity of reflux esophagitis and esophageal dysmotility and evaluate the effect of prolonged treatment with proton pump inhibitor (lansoprazole 30 mg/day) on esophageal motility in patients with severe reflux esophagitis associated with esophageal motility disorder." | 3.74 | Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. ( Hou, XH; Song, GQ; Xie, XP; Xu, JY, 2007) |
| "We aimed to examine the proportion of gastroesophageal reflux disease (GERD) in young patients with NCCP compared to the average-aged NCCP patients and to evaluate their symptomatic characteristics and the clinical efficacy of a 2-week proton pump inhibitor (PPI) trial." | 2.77 | Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain. ( Hong, SN; Kim, JH; Kim, SI; Ko, SY; Lee, JH; Lee, KJ; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, SY | 1 |
| Kim, SI | 1 |
| Kim, JH | 1 |
| Lee, JH | 1 |
| Lee, KJ | 1 |
| Hong, SN | 1 |
| Lee, SY | 1 |
| Sung, IK | 1 |
| Park, HS | 1 |
| Shim, CS | 1 |
| Borjesson, M | 1 |
| Rolny, P | 1 |
| Mannheimer, C | 1 |
| Pilhall, M | 1 |
| Xu, JY | 2 |
| Xie, XP | 2 |
| Hou, XH | 2 |
| Song, GQ | 1 |
2 trials available for lansoprazole and Esophageal Dysmotility
| Article | Year |
|---|---|
Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Chest Pain; Chi-Square Distribution; En | 2012 |
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents | 2003 |
2 other studies available for lansoprazole and Esophageal Dysmotility
| Article | Year |
|---|---|
[Role of esophageal motility abnormalities in severe reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophageal Moti | 2005 |
Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophageal Motility Disorders; Eso | 2007 |